Department of Nuclear Medicine, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia.
The Chair of Pharmaceutical Chemistry Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000, Ljubljana, Slovenia.
ChemMedChem. 2021 Jan 8;16(1):155-163. doi: 10.1002/cmdc.202000392. Epub 2020 Aug 3.
The cholecystokinin-2/gastrin receptor (CCK R) is considered a suitable target for the development of radiolabelled antagonists, due to its overexpression in various tumours, but no such compounds are available in clinical use. Therefore, we designed novel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated ligands based on CCK R antagonist Z360/nastorazepide. As a proof of concept that CCK R antagonistic activity can be retained by extending the Z360/nastorazepide structure using suitable linker, we present herein three compounds containing various PEG linkers synthesised on solid phase and in solution. The antagonistic properties were measured in a functional assay in the A431-CCK R cell line (in the presence of agonist G17), with IC values of 3.31, 4.11 and 10.4 nM for compounds containing PEG , PEG and PEG , respectively. All compounds were successfully radiolabelled with indium-111, lutetium-177 and gallium-68 (incorporation of radiometal >95 %). The gallium-68-labelled compounds were stable for up to 2 h (PBS, 37 °C). log D values were determined for indium-111- and gallium-68-labelled compounds, showing improved hydrophilicity compared to the reference compound.
胆囊收缩素-2/胃泌素受体(CCK R)被认为是开发放射性标记拮抗剂的合适靶点,因为它在各种肿瘤中过度表达,但目前临床上尚无此类化合物。因此,我们基于 CCK R 拮抗剂 Z360/nastorazepide 设计了新型的 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸缀合配体。作为使用合适的接头扩展 Z360/nastorazepide 结构可以保留 CCK R 拮抗活性的概念验证,我们在此介绍了三种在固相和溶液中合成的含有各种 PEG 接头的化合物。在 A431-CCK R 细胞系(在激动剂 G17 的存在下)中的功能测定中测量了拮抗性质,化合物含有 PEG 、PEG 和 PEG 的 IC 值分别为 3.31、4.11 和 10.4 nM。所有化合物均成功用铟-111、镥-177 和镓-68 进行放射性标记(放射性金属的掺入率>95%)。镓-68 标记的化合物在 PBS(37°C)中稳定长达 2 小时。确定了铟-111-和镓-68 标记化合物的 logD 值,与参比化合物相比显示出改善的亲水性。